Currently, the sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are guidelines-endorsed oral antihyperglycemic drugs for individuals with type 2 diabetes mellitus (T2DM), have garnered attention due to their beneficial impact on cardiorenal outcomes, kidney and cardiovascular function 1-5. Here, SLC5A2 is linked to diabetes mellitus.